Glivec: Phase I data; NDA under review

In a dose-escalating U.S. Phase I trial of Glivec in 83 patients with chronic phase

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE